Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?

Diabetologia

Volumn 58, Issue 8, 2015, Pages 1740-1744

  Ahrén, Bo ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Combination therapy; DPP 4 inhibition; GLP 1 receptor agonists; Insulin; Metformin; SGLT 2 inhibition; Sulfonylurea; Thiazolidinediones; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; INSULIN; METFORMIN; SULFONYLUREA; GLUCOSE BLOOD LEVEL;

ABSORPTION; EDITORIAL; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; STOMACH EMPTYING; DIABETES MELLITUS, TYPE 2;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84937525383     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3557-0     Document Type: Editorial

References (13)

1. Inzucchi SE, Bergenstal RM, Buse JB et al (2015) Management of hyperglycaemia in type 2 diabetes. 2015: a patient-centred approach: update to a position statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetologia 58:429–442
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589
3. Kahn SE, Cooper ME, del Prato S (2014) Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383:1068–1083
4. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R (2011) Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 54:2506–2514
5. Tahrani AA, Bailey C, del Prato S, Barnett AH (2014) Management of type 2 diabetes: new and future developments in treatment. Lancet 378:182–197
6. Rosenwasser RF, Sultan S, Sutton D, Choksi R, Epstein BJ (2013) SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes 6:453–467
7. Ahrén B (2013) Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag 9:155–163
8. Petrie JR (2013) The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovasc Diabetol 12:130
9. Zinman B (2011) Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time? Am J Med 124(Suppl 1):S19–S34
10. Ahrén B (2008) Novel combination treatment of type 2 diabetes. DPP-4 inhibition + metformin. Vasc Health Risk Manag 4:383–394
11. Deacon CF, Mannucci E, Ahrén B (2012) Glycemic efficacy of GLP-1 receptor agonists and DPP-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes – a review and meta analysis. Diabetes Obes Metab 14:762–767
12. Ahrén B (2014) Insulin plus incretin. A glucose-lowering strategy for type 2-diabetes. World J Diabetes 15:40–51
13. Halban PA, Polonsky KS, Bowden DW et al (2014) β-Cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. J Clin Endocrinol Metab 99:1983–1992